As per the terms of the agreement, NovaBiotics is expected to expand its product portfolio by working with Isogenica on two research projects, one concerning peptide selection and the other concerning peptide maturation.
Isogenica CEO Kevin Matthews said that as a result of such partnerships we are discovering active candidates for drug development.
NovaBiotics founder Deborah O’Neil said that their CIS–Display technology is ideal for screening NovaBiotic’s library of anti-infective peptides as efficiently as possible and enabling NovaBiotics to fast-track the development of its product pipeline.